Download PDF
Pharmacopsychiatry 2011; 44(4): 148-157
DOI: 10.1055/s-0031-1279739
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Proton Magnetic Resonance Spectroscopy Study of Brain Metabolite Changes after Antipsychotic Treatment

A. Szulc1 , B. Galinska1 , E. Tarasow2 , N. Waszkiewicz1 , B. Konarzewska1 , R. Poplawska1 , D. Bibulowicz1 , K. Simonienko1 , J. Walecki3
  • 1Department of Psychiatry, Medical University of Bialystok, Choroszcz, Poland
  • 2Department of Radiology, Medical University of Bialystok, Bialystok, Poland
  • 3Polish Academy of Sciences, Medical Research Centre, Warsaw, Poland
Further Information

Publication History

received 23.08.2010 revised 02.04.2011

accepted 04.04.2011

Publication Date:
27 June 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Proton magnetic resonance spectroscopy (1H MRS) enables the observation of brain function in vivo. The aim of our study was to evaluate the effects of antipsychotic medication on metabolite levels in the brain of schizophrenic patients based on a 1H MRS examination.

Methods: We examined 42 patients previously diagnosed with chronic schizophrenia twice: firstly, after the neuroleptic wash-out (baseline) and secondly, under stable medication (follow-up, after treatment). The study had a naturalistic design and several different neuroleptic medications were used during the treatment phase. The clinical evaluation, MRI and MRS procedures were performed. The group of 26 healthy controls were also examined to compare MRS results.

Results: We found a significantly lower NAA/Cr (N-acetylaspartate/creatine) ratio in the frontal lobe and thalamus in patients (after the wash-out) as compared to controls. After treatment a significant decrease of the Glx/Cr ratio in the temporal lobe and a trend for an increase of the NAA/Cr ratio in the thalamus were observed.

Conclusion: >Our results confirm that antipsychotic medication modifies brain metabolism measured by means of 1H MRS. The pattern of the changes suggests a neuroprotective action of antipsychotic medication in schizophrenia.

Key words

schizophrenia - antipsychotic treatment - proton magnetic resonance spectroscopy

References

  • 1 Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale.  Br J Psychiatry. 1993;  63 (suppl 22) 39-44
    PubMedGoogle Scholar
  • 2 Arun P, Madhavarao CN, Moffet JR. et al . Antipsychotic drugs increase N-acetylaspartyloglutamate in SH-SY5Y human neuroblastoma cells.  J Neurochem. 2008;  106 1669-1680
    CrossrefPubMedGoogle Scholar
  • 3 Auer DP, Wilke M, Grabner A. et al . Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H MRS and tissue segmentation.  Schizophr Res. 2001;  52 87-99
    CrossrefPubMedGoogle Scholar
  • 4 Aydin K, Urok A, Cakir S. Quantitative proton MRI spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection.  Am J Neuroradiol. 2007;  28 1968-1974
    CrossrefPubMedGoogle Scholar
  • 5 Bartha R, Williamson PC, Drost DJ. et al . Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton resonance spectroscopy.  Arch Gen Psychiatry. 1997;  54 959-965
    CrossrefPubMedGoogle Scholar
  • 6 Bastianetto S, Danik M, Mennicken F. et al . Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.  BMC Neurosci. 2006;  28 1-10
    PubMedGoogle Scholar
  • 7 Bazire S. Psychotropic Drug Directory 2003/2004. The professionals’ pocket handbook and aide memoire. UK Fivepin Publishing; 2003: 179-181
    Google Scholar
  • 8 Bertolino A, Weinberger DR. Proton magnetic resonance spectroscopy in schizophrenia.  Eur J Radiol. 1999;  30 132-141
    CrossrefPubMedGoogle Scholar
  • 9 Bertolino A, Callicott JH, Mattay VS. et al . The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia.  Biol Psychiatry. 2001;  49 39-46
    CrossrefPubMedGoogle Scholar
  • 10 Bertolino A, Ciota D, Brudaglio F. et al . Working memory deficits and levels of N-Acetylaspartate in patients with schizophreniform disorder.  Am J Psychiatry. 2003;  160 483-489
    CrossrefPubMedGoogle Scholar
  • 11 Brambilla P, Stanley JA, Nicoletti M. et al . 1H MRS brain measures and acute lorazepam administration in healthy human subjects.  Neuropsychopharmacol. 2002;  26 546-551
    CrossrefPubMedGoogle Scholar
  • 12 Braus DF, Ende G, Weber-Fahr W. et al . Favorable effect on neuronal viability in the anterior cingulated gyrus due to long-term treatment with atypical antipsychotics: an MRSI study.  Pharmacopsychiatry. 2001;  34 251-253
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Braus DF, Ende G, Weber-Fahr W. et al . Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia.  Neuropsychopharmacol. 2002;  12 145-152
    PubMedGoogle Scholar
  • 14 Burlina AP, Skaper Mazza MR, Ferrari V. et al . N-acetylaspartylglutamate selectively inhibits neuronal response to N-methyl-D-aspartic acid in vitro.  J neurochem. 1994;  63 1174-1177
    PubMedGoogle Scholar
  • 15 Bustillo JR, Lauriello J, Rowland LM. et al . Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia.  Psychiatry Res. 2001;  107 135-149
    CrossrefPubMedGoogle Scholar
  • 16 Bustillo JR, Rowland LM, Lauriello J. et al . High choline concentrations in the caudate nucleus in antipsychotic-naïve patients with schizophrenia.  Am J Psychiatry. 2002;  159 130-133
    CrossrefPubMedGoogle Scholar
  • 17 Bustillo JR, Lauriello J, Rowland LM. et al . Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure.  Schizophr Res. 2002;  58 313-321
    CrossrefPubMedGoogle Scholar
  • 18 Bustillo J, Wolff C, Gutierrez AM. et al . Treatments of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels.  Schizophr Res. 2004;  66 31-39
    CrossrefPubMedGoogle Scholar
  • 19 Bustillo J, Barrow R, Paz R. et al . Long-term treatment of rats with haloperidol: lack of effect on brain N-acetyl aspartate levels.  Neuropsychopharmacol. 2006;  31 751-756
    CrossrefPubMedGoogle Scholar
  • 20 Bustillo JR, Rowland LM, Jung R. et al . Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.  Neuropsychopharmacol. 2008;  33 2456-2466
    CrossrefPubMedGoogle Scholar
  • 21 Bustillo JR, Rowland LM, Mullins P. et al . (1)H-MRS at 4 Tesla in minimally treated early schizophrenia.  Mol Psychiatry. 2010;  15 629-636
    CrossrefPubMedGoogle Scholar
  • 22 Carlsson A, Hansson LO, Waters N. et al . A glutamatergic deficiency in schizophrenia.  Br J Psychiatry. 1999;  (Suppl. 37) 2-6
    PubMedGoogle Scholar
  • 23 Chakos MH, Schobel SA, Gu H. et al . Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia.  Br J Psychiatry. 2005;  186 24-31
    PubMedGoogle Scholar
  • 24 Choe B, Suh TS, Shin KS. et al . Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy.  Invest Radiol. 1996;  31 345-352
    CrossrefPubMedGoogle Scholar
  • 25 Deicken RF, Zhou L, Corwin F. et al . Decreased left frontal lobe N-acetylaspartate in schizophrenia.  Am J Psychiatry. 1997;  154 688-690
    PubMedGoogle Scholar
  • 26 Deicken RF, Zhou L, Schuff N. et al . Proton magnetic resonance spectroscopy of the anterior cingulated region in schizophrenia.  Schizophr Res. 1997;  27 65-71
    CrossrefPubMedGoogle Scholar
  • 27 Deicken RF, Zhou L, Schuff N. et al . Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy.  Biol Psychiatry. 1998;  43 483-488
    CrossrefPubMedGoogle Scholar
  • 28 Deicken RF, Pegues M, Amend D. Reduced hippoacampal N-acetylaspartate without volume loss in schizophrenia.  Schizophr Res. 1999;  37 217-223
    CrossrefPubMedGoogle Scholar
  • 29 Deicken RF, Johnson C, Eliaz Y. et al . Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia.  Am J Psychiatry. 2000;  157 644-647
    CrossrefPubMedGoogle Scholar
  • 30 Deicken RF, Feiwell R, Schaff N. et al . Evidence for altered cerebellar vermis neuronal integrity in schizophrenia.  Psychiatry Res Neuroimaging. 2001;  107 125-134
    CrossrefPubMedGoogle Scholar
  • 31 Delamillieure P, Fernandez J, Constans JM. et al . Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report.  Am J Psychiatry. 2000;  157 641-643
    CrossrefPubMedGoogle Scholar
  • 32 Eastwood SL, Peter RHP, Harrison PJ. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain.  Neurosci Lett. 1996;  212 163-166
    CrossrefPubMedGoogle Scholar
  • 33 Edden RAE, Pomper MG, Barker PB. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla.  Magnetic Reson Med. 2007;  57 977-982
    PubMedGoogle Scholar
  • 34 Ende G, Braus DF, Walter S. et al . Effects of age medication and illness duration on the N-acetylaspartate signal of the anterior cingulate region in schizophrenia.  Schizophr Res. 2000;  41 389-395
    CrossrefPubMedGoogle Scholar
  • 35 Ende G, Braus DF, Walter S. et al . Lower concentration of thalamic N-acetylaspartate in patients with schizophrenia: a replication study.  Am J Psychiatry. 2001;  158 1314-1316
    CrossrefPubMedGoogle Scholar
  • 36 Ende G, Braus DF, Walter S. et al . Multiregional 1H-MRSI of the hippocampus thalamus and basal ganglia in schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 2003;  253 9-15
    CrossrefPubMedGoogle Scholar
  • 37 Ertugrul A, Ulug B. The effect of clozapina on neuroimaging findings in schizophrenia.  Psychiatr Danub. 2007;  19 367-369
    PubMedGoogle Scholar
  • 38 Ertugrul A, Volkan-Salanci B, Basar K. et al . The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: Relationship with treatment response.  Psych Res Neuroimaging. 2009;  174 121-129
    CrossrefPubMedGoogle Scholar
  • 39 Fannon D, Simmons A, Tennakoon L. et al . Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naïve patients with schizophrenia.  Biol Psychiatry. 2003;  54 587-598
    CrossrefPubMedGoogle Scholar
  • 40 First MB, Spitzer RL, Gibbon M. et al .Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Press, Washington DC; 1997
    Google Scholar
  • 41 Fukuzako H, Kodama S, Fukuzako T. et al . Subtype-associated metabolite differences in the temporal lobe in schizophrenia detected by proton magnetic resonance spectroscopy.  Psychiatry Res Neuroimaging. 1999;  92 45-56
    CrossrefPubMedGoogle Scholar
  • 42 Galinska B, Szulc A, Tarasow E. et al . Relationship between frontal N-acetylaspartate and cognitive deficit in first-episode schizophrenia.  Med Sci Monit. 2007;  13 (S 01) 11-16
    PubMedGoogle Scholar
  • 43 Glodzik-Sobanska L, Słowik A, McHugh P. et al . Single voxel proton magnetic resonance spectroscopy in post-stroke depression.  Psychiatry Res Neuroimaging. 2006;  148 11-120
    CrossrefPubMedGoogle Scholar
  • 44 Goff DC, Coyle JT. The emerging role of glutamatein the pathophysioogy and treatment of schizophrenia.  Am J Psychiatry. 2001;  158 1367-1377
    CrossrefPubMedGoogle Scholar
  • 45 Goff DC, Hennen J, Lyoo IK. et al . Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.  Biol Psychiatry. 2002;  51 493-497
    CrossrefPubMedGoogle Scholar
  • 46 Guy W. ECDEU Assessment Manual for Psychopathology.  DHEW Publ ADM-76-338 1976;  534-537
    PubMedGoogle Scholar
  • 47 Harte MK, Bachus SB, Reynolds GP. Increased N-acetylaspartate in rat striatum following long term administration of haloperidol.  Schizophr Res. 2005;  75 303-308
    CrossrefPubMedGoogle Scholar
  • 48 Heimberg C, Komoroski RA, Lawson WB. et al . Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect.  Psychiatry Res Neuroimaging. 1998;  83 105-115
    CrossrefPubMedGoogle Scholar
  • 49 Hunsberger J, Austin DR, Henter ID. et al . The neurotrophic and neuroprotective effects of psychotropic agents.  Dialogues Clin Neurosci. 2009;  11 333-348
    PubMedGoogle Scholar
  • 50 Jakary A, Vinogradov S, Feiwell R. et al . N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI.  Schizophr Res. 2005;  76 173-185
    CrossrefPubMedGoogle Scholar
  • 51 Kaiser LG, Schuff N, Cashdollar N. et al . Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4T.  Neurobiol Aging. 2005;  26 665-672
    CrossrefPubMedGoogle Scholar
  • 52 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
    Google Scholar
  • 53 Keilhoff G, Grecksch G, Bernstein HG. et al . Risperidone and haloperidol promote survival of stem cells in the rat hippocampus.  Eur Arch Psychiatry Clin Neurosci. 2010;  260 151-162
    CrossrefPubMedGoogle Scholar
  • 54 Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings – part II.  Biol Psychiatry. 2000;  48 369-380
    Google Scholar
  • 55 Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.  Biol Psychiatry. 2001;  50 729-742
    CrossrefPubMedGoogle Scholar
  • 56 Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine and schizophrenia. from pathophysiology to treatment.  Ann NY Acad Sci. 2003;  1003 138-158
    CrossrefPubMedGoogle Scholar
  • 57 Laruelle M, Frankle WG, Narendran R. et al . Mechanism of action of antipsychotic drugs: from dopamine D2 receptor antagonism to glutamate NMDA facilitation.  Clin Ther. 2005;  27 (Suppl. A) S16-S24
    CrossrefPubMedGoogle Scholar
  • 58 Lieberman JA, Tollesfon GD, Charles C. et al . Antipsychotic drug effects on brain morphology in first-episode psychosis.  Arch Gen Psychiatry. 2005;  62 361-370
    CrossrefPubMedGoogle Scholar
  • 59 Lindquist DM, Hawk RM, Karson CR. et al . Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo.  Magn Reson Med. 2000;  43 355-358
    CrossrefPubMedGoogle Scholar
  • 60 Molteni F, Calabrese F, Racagni G. et al . Antipsychotic drug action on gene modulation and signaling mechanisms.  Pharmacol Ther. 2009;  124 74-85
    CrossrefPubMedGoogle Scholar
  • 61 Ohrmann P, Siegmund A, Suslow T. et al . Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.  Schizophr Res. 2005;  73 153-157
    CrossrefPubMedGoogle Scholar
  • 62 Ohrmann P, Siegmund A, Suslow T. et al . Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study.  J Psych Res. 2007;  41 625-634
    CrossrefPubMedGoogle Scholar
  • 63 Ohrmann P, Kugel H, Bauer J. et al . Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy.  Schizophr Res. 2008;  106 156-163
    CrossrefPubMedGoogle Scholar
  • 64 Omori M, Murata T, Kiura H. et al . Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy.  Psychiatry Res Neuroimaging. 2000;  98 155-162
    CrossrefPubMedGoogle Scholar
  • 65 O’Neill J, Levitt J, Caplan R. et al . 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia.  Neuroimage. 2004;  21 1781-1789
    CrossrefPubMedGoogle Scholar
  • 66 Ossowska K, Pietraszek M, Wardas J. et al . Chronic treatment with haloperidol and clozapine alter the level of NMDA-R1 mRNA In the rat brain: an in situ hybridization study.  Pol J Pharmacol. 2002;  54 1-9
    PubMedGoogle Scholar
  • 67 Pae CU, Choe BY, Joo RH. et al . Neuronal dysfunction of the frontal lobe in schizophrenia.  Neuropsychobiology. 2004;  50 211-215
    CrossrefPubMedGoogle Scholar
  • 68 Park SW, Lee JG, Ha EK. et al . Differential effects of aripiprazole and haloperidol on BDBF-mediated signal changes in SH-SY5Y cells.  Eur Neuropsychopharmacol. 2009;  19 356-362
    CrossrefPubMedGoogle Scholar
  • 69 Pouwels PJW, Frahm J. Differential distribution of NAA and NAAG in Human brain as determined by quantitative localized proton MRS.  NMR Biomed. 1997;  10 73-78
    CrossrefPubMedGoogle Scholar
  • 70 Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research.  Brain Res Rev. 2004;  44 83-102
    CrossrefPubMedGoogle Scholar
  • 71 Ross AJ, Sachdev PS, Wen W. et al . Cognitive correlates of 1H MRS measures in the healthy elderly brain.  Brain Res Bull. 2005;  66 9-16
    CrossrefPubMedGoogle Scholar
  • 72 Sanches RF, Crippa JA, Hallak JE. et al . Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology.  Rev Hosp Clin Fac Med Sao Paulo. 2004;  59 145-152
    CrossrefPubMedGoogle Scholar
  • 73 Scherk H, Falkai P. Effects of antipsychotics on brain structure.  Curr Opin Psychiatry. 2006;  19 145-150
    CrossrefPubMedGoogle Scholar
  • 74 Seeman P, Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons.  Science. 1975;  188 1217-1219
    CrossrefPubMedGoogle Scholar
  • 75 Sesack SR, Carr DB, Omelchenko N. et al . Anatomical substrates for glutamate-dopamine interactions. evidence for specificity of connections and extrasynaptic actions.  Ann NY Acad Sci. 2003;  1003 36-52
    CrossrefPubMedGoogle Scholar
  • 76 Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.  Neuropsychopharmacol. 2005;  30 1949-1962
    CrossrefPubMedGoogle Scholar
  • 77 Szulc A, Galinska B, Tarasow E. et al . Glutamatergic system dysfunction in schizophrenia: A proton magnetic resonance spectroscopy (1H MRS) study.  Pol J Radiol. 2004;  69 33-36
    PubMedGoogle Scholar
  • 78 Szulc A, Galinska B, Tarasow E. et al . The effect of risperidone on metabolite measures in the frontal lobe temporal lobe and thalamus in schizophrenic – a proton magnetic resonance spectroscopy (1H MRS) study.  Pharmacopsychiatry. 2005;  38 214-219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Szulc A, Galinska B, Tarasow E. et al . N-acetylaspartate (NAA) levels In selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.  Med Sci Monit. 2007;  13 (S 01) 17-22
    PubMedGoogle Scholar
  • 80 Tanaka Y, Obata T, Sassa T. et al . Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.  Psych Clin Neurosci. 2006;  60 365-372
    CrossrefPubMedGoogle Scholar
  • 81 Tarasow E, Kubas B, Walecki J. MR proton spectroscopy in patients with CNS involvement In Bournevilleâs disease.  Med Sci Monit. 2001;  7 762-765
    PubMedGoogle Scholar
  • 82 Tarasow E, Wiercinska-Drapało A, Kubas B. et al . Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients.  Acta Radiol. 2003;  44 206-212
    CrossrefPubMedGoogle Scholar
  • 83 Tebartz van Elst L, Valerius G, Buchert M. et al . Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.  Biol Psychiatry. 2005;  58 724-730
    CrossrefPubMedGoogle Scholar
  • 84 Théberge J, Bartha R, Drost DJ. et al . Glutamate and glutamine measured with 40 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.  Am J Psychiatry. 2002;  159 1944-1946
    CrossrefPubMedGoogle Scholar
  • 85 Théberge J, Al-Semaan Y, Williamson PC. et al . Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 40-T proton MRS.  Am J Psychiatry. 2003;  160 2231-2233
    CrossrefPubMedGoogle Scholar
  • 86 Théberge J, Williamson KE, Aoyama N. et al . Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia.  Br J Psychiatry. 2007;  191 325-334
    CrossrefPubMedGoogle Scholar
  • 87 Tibbo P, Hanstock C, Valiakalavil A. et al . 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.  Am J Psychiatry. 2004;  161 1116-1118
    CrossrefPubMedGoogle Scholar
  • 88 Tsai SJ. Central N-acetylaspartylglutamate deficit: a possible pathogenesis of schizophrenia.  Med Sci Monit. 2005;  11 39-45
    PubMedGoogle Scholar
  • 89 Urenjak J, Williams SR, Gadian DG. et al . Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro.  J Neurochem. 1992;  59 5-61
    PubMedGoogle Scholar
  • 90 Wood SJ, Berger GE, Wellard RM. et al . A 1H MRS investigation of the medial temporal lobe In antipsychotic-naive and early treated first episode psychosis.  Schizophr Res. 2008;  102 163-170
    PubMedGoogle Scholar
  • 91 Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics.  J Clin Psychiatry. 2003;  64 663-667
    CrossrefPubMedGoogle Scholar
  • 92 Xi ZX, Baker DA, Shen H. et al . Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens.  J Pharamacol Exp Ther. 2002;  300 162-171
    PubMedGoogle Scholar
  • 93 Zhao J, Ramadan E, Cappiello M. et al . NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance.  Eur J Neurosci. 2001;  13 340-346
    PubMedGoogle Scholar
  • 94 Zhong C, Zhao X, Van KC. et al . NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsolateral hippocampus following fluid percussion injury in the rat.  J Neurochem. 2006;  97 1015-1025
    CrossrefPubMedGoogle Scholar

Correspondence

Dr. A. Szulc

Department of Psychiatry

Medical University in Bialystok

16-070 Choroszcz

Poland

Phone: +48/85/719 39 77

Fax: +48/85/719 39 77

Email: agataszulc@poczta.onet.pl

Email: agata.szulc@umwb.edu.pl

      >